AstraZeneca, a leading global biopharmaceutical company, has announced plans to invest $300 million in a new 84,000-square-foot manufacturing facility in Rockville, MD. This state-of-the-art facility will serve as the launch site for the company’s cell therapy platforms in the U.S., specifically for critical cancer trials and future commercial supply.
The location of this facility at 9950 Medical Center Dr. is strategic as it is situated within Maryland’s life sciences corridor and less than five miles from one of AstraZeneca’s five global R&D centers. The site is expected to be operational by 2026 and will create over 150 highly skilled jobs initially focused on manufacturing T-cell therapies for clinical trials worldwide.
Governor Wes Moore of Maryland expressed excitement about this investment stating that AstraZeneca’s commitment to innovation aligns perfectly with the state’s own dedication to fostering growth in the life sciences sector. He believes that this significant investment will not only maintain Maryland’s leadership position but also enhance its competitive edge.
This announcement marks another milestone for AstraZeneca following their recent full-building lease signing in Gaithersburg. With no mention of specific organizations or programs, we can expect more exciting developments from them soon.
